首页> 外文期刊>海南医科大学学报(英文版) >Effects of Liraglutide on endothelial function, immune function and related factors in patients with type 2 diabetes mellitus
【24h】

Effects of Liraglutide on endothelial function, immune function and related factors in patients with type 2 diabetes mellitus

机译:利拉鲁肽对2型糖尿病患者内皮功能,免疫功能及相关因子的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To investigate the effects of Liraglutide on endothelial function, immune function and related factors in patients with type 2 diabetes mellitus. Methods: A total of 160 patients with type 2 diabetes mellitus who received treatment in department of endocrinology of our hospital from December 2015 to June 2018 were collected. They were randomly divided into the control group and the observation group, 80 cases in each group. The patients in the control group were treated with metformin. The patients in the observation group were treated with liraglutide on the basis of the control group. The levels of endothelin (ET-1), nitric oxide (NO), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin G (IgG), hypersensitive C-reactive protein (hs-CRP), insulin-like growth factor-1 (IGF-1), tumor necrosis factor- (TNF-α), Vaspin and HbAlc were detected and compared. Results: After treatment, compared with the treatment group, the serum levels of ET-1, hs-CRP, IGF-1, TNF-α and HbAlc of patients in the control group and the observation group were significantly decreased, and the levels of NO, IgA, IgG, IgM and Vaspin increased significantly. The change trend of the above indexes of patients in the observation group was more obvious than those in the control group (P<0.05). Conclusion: Liraglutide combined with metformin in the treatment of type 2 diabetes mellitus can significantly enhance endothelial function and immune function of patients, and alleviate inflammation, and it has good clinical efficacy.
机译:目的:探讨利拉鲁肽对2型糖尿病患者内皮功能,免疫功能及相关因素的影响。方法:收集2015年12月至2018年6月我院内分泌科收治的160例2型糖尿病患者的资料。将他们随机分为对照组和观察组,每组80例。对照组患者接受二甲双胍治疗。观察组在对照组的基础上给予利拉鲁肽治疗。内皮素(ET-1),一氧化氮(NO),免疫球蛋白A(IgA),免疫球蛋白M(IgM),免疫球蛋白G(IgG),超敏C反应蛋白(hs-CRP),胰岛素样生长因子的水平检测并比较-1(IGF-1),肿瘤坏死因子-(TNF-α),Vaspin和HbAlc。结果:治疗后,对照组和观察组患者的血清ET-1,hs-CRP,IGF-1,TNF-α和HbAlc水平较治疗组明显降低,且血清NO,IgA,IgG,IgM和Vaspin明显增加。观察组患者上述各项指标的变化趋势较对照组明显(P <0.05)。结论:利拉鲁肽联合二甲双胍治疗2型糖尿病可明显增强患者的内皮功能和免疫功能,减轻炎症反应,具有良好的临床疗效。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2019年第3期|27-30|共4页
  • 作者单位

    Department of Endocrinology, Yancheng First People's Hospital, Yancheng, 224006, Jiangsu Province, China;

    Department of Endocrinology, Yancheng First People's Hospital, Yancheng, 224006, Jiangsu Province, China;

    Department of Endocrinology, Yancheng First People's Hospital, Yancheng, 224006, Jiangsu Province, China;

    Department of Endocrinology, Yancheng First People's Hospital, Yancheng, 224006, Jiangsu Province, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号